SCHEMBL2322286

SCHEMBL2322286

O=S(=O)(O)c1ccc(O)c(-c2ccccc2P(c2ccccc2)c2ccccc2)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 4/20 0.43
ALDH1A1 P00352 3/20 0.43
KDM4E B2RXH2 1/20 0.43
HPGD P15428 1/20 0.43
PKLR P30613 2/20 0.39
TSHR P16473 3/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
SNCA P37840 1/20 0.37
POLB P06746 2/20 0.36
CYP2D6 P10635 1/20 0.36
SERPINE1 P05121 2/20 0.35
NSD2 O96028 1/20 0.35
DUSP3 P51452 1/20 0.35
PTPN5 P54829 1/20 0.35
CASP7 P55210 1/20 0.35
CASP6 P55212 1/20 0.35
PTPN11 Q06124 1/20 0.35
LMNA P02545 1/20 0.34
APEX1 P27695 1/20 0.34
CYP1A2 P05177 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18295943 0.84 TSHR (0.47) HSD17B10ALDH1A1KDM4EHPGDPKLR
SCHEMBL8516332 0.81 HSD17B10 (0.53) HSD17B10ALDH1A1KDM4EHPGDPKLR
SCHEMBL16502275 0.81 TSHR (0.44) HSD17B10ALDH1A1KDM4EHPGDTSHR
SCHEMBL8516709 0.79 ALDH1A1 (0.63) HSD17B10ALDH1A1KDM4EHPGDPKLR
SCHEMBL30422061 0.77 ALDH1A1 (0.46) HSD17B10ALDH1A1KDM4EHPGDSMN1; SMN2
SCHEMBL2322069 0.77 ALDH1A1 (0.46) HSD17B10ALDH1A1KDM4EHPGDSMN1; SMN2
SCHEMBL10154144 0.76 TDP1 (0.37) ALDH1A1KDM4ETSHRSMN1; SMN2SNCA
SCHEMBL14639550 0.76 SERPINE1 (0.39) HSD17B10ALDH1A1KDM4EHPGDPKLR
SCHEMBL8367520 0.76 BACE1 (0.54) HSD17B10ALDH1A1KDM4EHPGDPKLR
SCHEMBL1120987 0.73 CYP3A4 (0.58) KDM4EGAATDP1ESR1ESR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1899289-B1 METHOD FOR PRODUCING ARYL AMINES, ARYL ETHERS AND ARYL THIOETHERS ARCHIMICA GMBH (DE) 2011-08-10 EP disclosed
US-20080306260-A1 Method for Producing Aryl Amines, Aryl Ethers and Aryl Thioethers ARCHIMICA GMBH (DE) 2008-12-11 US disclosed
EP-1937613-A1 PROCESS FOR PREPARING 2-ARYLCARBONYL COMPOUNDS, 2-ARYL ESTERS AND 2-ARYLNITRILES AND THEIR HETEROAROMATIC ANALOGUES Archimica GmbH (DE) 2008-07-02 EP disclosed
EP-1899289-A1 METHOD FOR PRODUCING ARYL AMINES, ARYL ETHERS AND ARYL THIOETHERS Archimica GmbH (DE) 2008-03-19 EP disclosed
WO-2007033781-A1 PROCESS FOR PREPARING 2-ARYLCARBONYL COMPOUNDS, 2-ARYL ESTERS AND 2-ARYLNITRILES AND THEIR HETEROAROMATIC ANALOGUES ARCHIMICA GMBH (DE) 2007-03-29 WO disclosed
WO-2007000250-A1 METHOD FOR PRODUCING ARYL AMINES, ARYL ETHERS AND ARYL THIOETHERS ARCHIMICA GMBH (DE) 2007-01-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080306260-A1 Method for Producing Aryl Amines, Aryl Ethers and Aryl Thioethers TST, TAAR1, TSHR HSD17B10 2724/4885ALDH1A1 1524/4885KDM4E 3193/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.